Thus far, there were no biomarkers for predicting the efficacy of anti-PD-1 therapy in esophageal cancer, although PD-L1 expression has been used to guide anti-PD-1 therapy in non-small cell lung cancer without driver gene mutations (29). The gene discussed is CD274; the disease is non-small cell lung carcinoma.